Dali Pharmaceutical Co Ltd
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company's products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections. It also has patents, including invention patents and utility models. The company was founded in 1996 and is headquartered in Dali,… Read more
Dali Pharmaceutical Co Ltd (603963) - Total Liabilities
Latest total liabilities as of September 2024: CN¥88.81 Million CNY
Based on the latest financial reports, Dali Pharmaceutical Co Ltd (603963) has total liabilities worth CN¥88.81 Million CNY as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dali Pharmaceutical Co Ltd - Total Liabilities Trend (2012–2023)
This chart illustrates how Dali Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dali Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Dali Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RIV Capital Inc
PINK:CNPOF
|
USA | $160.75 Million |
|
Kairous Acquisition Corp Ltd
NASDAQ:KACL
|
USA | $7.09 Million |
|
Helios Energy Ltd
AU:HE8
|
Australia | AU$2.56 Million |
|
Arika Resources Ltd
AU:ARI
|
Australia | AU$1.59 Million |
|
Innosimulation Co., Ltd
KQ:274400
|
Korea | ₩28.32 Billion |
|
Dunia Virtual Online Tbk Pt
JK:AREA
|
Indonesia | Rp48.41 Billion |
|
Agillic A/S
CO:AGILC
|
Denmark | Dkr63.20 Million |
|
Santa Fe Minerals Ltd
AU:SFM
|
Australia | AU$210.23K |
Liability Composition Analysis (2012–2023)
This chart breaks down Dali Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dali Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dali Pharmaceutical Co Ltd (2012–2023)
The table below shows the annual total liabilities of Dali Pharmaceutical Co Ltd from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | CN¥92.71 Million | -9.40% |
| 2022-12-31 | CN¥102.33 Million | -21.22% |
| 2021-12-31 | CN¥129.89 Million | +20.43% |
| 2020-12-31 | CN¥107.86 Million | +15.10% |
| 2019-12-31 | CN¥93.71 Million | -28.13% |
| 2018-12-31 | CN¥130.38 Million | -12.69% |
| 2017-12-31 | CN¥149.34 Million | +87.90% |
| 2016-12-31 | CN¥79.48 Million | -27.92% |
| 2015-12-31 | CN¥110.26 Million | +25.07% |
| 2014-12-31 | CN¥88.16 Million | -6.35% |
| 2013-12-31 | CN¥94.14 Million | -29.29% |
| 2012-12-31 | CN¥133.13 Million | -- |